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Take home message  
People with reasonable function and heart/lung diseases are at risk of breathlessness, 
increasing at the end of life. 
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ABSTRACT 
Introduction: To explore trajectories of breathlessness intensity by function and life-limiting illness 
diagnosis in the last 3 weeks of life in palliative care patients.   
Methods: Prospective, consecutive cohort with point-of-care data of patients of Silver Chain Hospice 
Care 2011-2014 (n=4,638; 51,494 data points). Breathlessness intensity (0-10 Numerical Rating Scale 
(NRS)) and physical function (Australia-modified Karnofsky Performance Scale (AKPS)) were 
measured each visit. Time was anchored at death. Breathlessness trajectory was analysed by physical 
function and diagnosis using mixed effects regression. 
Results: Mean age was 71.5 (SD 15.1) years; 55.2% males; most with cancer. The last recorded 
AKPS was >40 for 26.8%. Breathlessness was worst in people with cardio-respiratory disease and 
AKPS >40, and breathlessness in the last week of life increased most in this group (adjusted mean 
2.92 versus all others 1.51; p=0.0001). The only significant interaction was with diagnosis and 
function in the last week of life (p<0.0001). 
 
Conclusions:  Breathlessness is more intense and increases more in people with better function and 
cardio-respiratory disease immediately before death. Whether there are reversible causes for these 
people should be explored prospectively. Omitting function from previous population estimates may 
have over-estimated breathlessness intensity for many patients in the days preceding death.       
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Introduction 
Chronic breathlessness affects one in eleven people in the general population.[1] For most people, this 
will be attributed to an underlying medical condition such as respiratory disease [2] which may be 
treatable but not curable, and which is likely to contribute to suffering near death.[3]  
Severe breathlessness is one of the most frightening experiences. Unlike other symptoms such as pain, 
an episode of severe breathlessness is often associated with an ongoing terror of imminent death.[4] It 
is therefore unsurprising that the mode of dying and, in particular, a fear of severe breathlessness or 
suffocation, may be a major anxiety for people with a life-limiting illness.[5] Many people may have 
vivid memories of a relative dying with serious respiratory distress, and past memories and fears 
affect central perception and anticipation of breathlessness.[6]  
In the weeks prior to death in a palliative care population, the prevalence and intensity of 
breathlessness is reported to increase and functional status most often worsens.[7,8] This phenomenon 
has been described in several datasets and includes people with a wide range of recorded causes of 
death including frailty, dementia and those perceived to have had a ‘sudden’ death.[9-12] To date, two 
cohort studies have proposed contradictory effects of performance status on chronic breathlessness at 
the end of life: one suggested that decreasing performance status is associated with the increasing 
breathlessness and the other, the opposite. [10,13] Given that no study has evaluated whether the 
trajectory of breathlessness differs in relation to the patient’s physical functional status and underlying 
condition(s) in the last weeks before death, and the role of functional status in the two studies that 
have been done to date were contradictory, this current study was conceived to explore this 
relationship.   
The relationship between breathlessness and functional status at the end of life is important to inform 
clinical discussions with concerned patients and their relatives, and to guide research in ways of best 
palliating breathlessness. At least two distinct trajectories of function and their relation to 
breathlessness need to be understood: 
i) progressive functional decline; and  
ii) sudden deterioration in the setting of a known life-limiting illness.[9,12]  
Such patterns may also provide important insights into the underlying pathologies leading to different 
trajectories of dying and the need to pay heed to symptom exacerbations even in the last weeks of life. 
 
The aim of this study was to evaluate patterns of breathlessness by levels of function in the last three 
weeks of life in palliative care. The null hypothesis was that there would be no difference in the 
trajectories of breathlessness intensity between diagnostic groups categorised by function in the 21 




Silver Chain Hospice Care Service (SCHCS) is the sole community palliative care provider for 
metropolitan Perth, Western Australia providing care for approximately 2,800 patients annually in 
their own homes. The SCHCS comprises an interdisciplinary team that includes general practitioners, 
registered nurses, care aides, volunteers, counsellors, and pastoral care workers. Registered nurses are 
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available 24 hours/day, 7 days/week, supported by clinical nurse consultants and other staff. The 
service is funded by the state government and is free of charge to palliative care patients.  
Study cohort and design 
This was a longitudinal study using all data on breathlessness and level of function, aggregated each 
day from a consecutive cohort of 7,896 patients seen by SCHCS between January 1, 2011 and 
December 31, 2014. There were 1095 patients who had no data recorded in the last 21 days of life.  
These patients were excluded, leaving 6,801 patients for analysis with 51,494 data points. [7,14,15] 
We included all data points collected in the last 21 days of life for everyone who died, with 
simultaneously recorded breathlessness intensity and functional scores, categorised into broad 
diagnostic groups. As the only time point that is constant in referral-dependent hospice and palliative 
care is death, [16] the longitudinal analysis used time anchored at death in this cohort of people whose 
expected outcome was death.  
 
Data collection from SCHCS records 
All data were collected in the clinical setting contemporaneously with each face-to-face visit by a 
health professional from the SCHCS. Processes including staff recording of patient rating of 
symptoms remained constant during the study period. De-identified data included:  
• Demographic and clinical data recorded once on admission to the service: 
o Demographic characteristics (age, gender, living arrangement, caregiver status, and place 
of death); 
o Dominant cause of life-limiting illness (cardio-respiratory diseases (primary lung cancer, 
respiratory disease, cardiac failure) and other); and 
• Clinical data recorded at each clinical encounter: 
o Patient-rated intensity of breathlessness on an 11-point numerical rating scale (NRS) 
between 0 (‘no’) to 10 (‘worst imaginable’) using the Symptom Assessment Scale (SAS) 
[17]; and 
o Clinician-rated performance status using the Australia-modified Karnofsky Performance Scale 
(AKPS) ranging from 100 (functioning normally and without symptoms or assistance) to 0 (dead) in 
10 point decrements. An AKPS of 40 indicates high levels of care for basic activities of daily living 
and a score of 20 represents almost total dependence on others for care. AKPS has been validated in 
palliative care populations.[18] 
o Patients were visited in their homes by clinicians as required.  This may have been on a weekly basis, 
every few days, daily or several times in one day.  Frequency of visits tend to increase as time of 
death approaches but depends on the needs of the patients and their families. 
 
Data quality was optimised by routine point-of-care data entry by SCHCH staff into mobile phone 
data systems for all fields relating to that clinical encounter. 
 
Statistical analyses 
The cohort and service characteristics were reported using descriptive statistics and were compared 
using Chi square analyses for categorical data and analysis of variance for continuous variables for 
normally distributed data and Kruskal-Wallis test for non-normally distributed data. Data were tested 
for normality by graphing them.  
.  
 
For each of the last 21 days of life, the intensity of breathlessness was compared between people with 
an AKPS ≤40 on that day and those with higher functional status, and between people with underlying 
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cardio-respiratory disease and those with other diseases. The secondary comparators were the 
trajectories of breathlessness by 10-point AKPS (10, 20, 30 or 40) in the last three weeks of life, 
further stratified by the presence of cardio-respiratory disease. Lung cancer was included in the 
cardiorespiratory group. 
 
The number of days from death was transformed into a three point categorical variable with the last 
seven days of data being included into week 1, week 2 including 8 to 14 days and week three 
including 15 to 21 days from death. 
 
Factors related to change in breathlessness were analysed using mixed effects regression accounting 
for repeated measurements, adjusted for age, gender, carer status, length of stay (from referral to the 
service until death) and diagnostic group. Interaction terms between week from death and 1) AKPS; 
2) cardiorespiratory diagnosis and; 3) both AKPS and cardiorespiratory diagnosis were evaluated by 
including interaction terms in the fully adjusted model. Mean differences in breathlessness intensity 
were presented with 95% confidence intervals (CI). No missing data were imputed. Statistical 
significance was defined as a two-sided p<0.05. Data were analysed using Stata version 14.0 
statistical analysis software (Stata Corporation, 2015, College Station, TX).  
 
Ethical considerations 
The study was approved by Silver Chain Human Research Ethics Committee. Given that these were 
aggregated, de-identified data, individual consent was not required. This paper is reported using the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [19]. 
 
RESULTS 
In total, 6,801 people were included in the analysis generating 51,494 data points in the last 21 days of 
life; 55.2% males, mean age at death 71.5 (SD 15.1) years, and mean time from referral to death 78.4 
(SD 107.1) days (Table 1). Most people had cancers as their documented life-limiting illness 
(5,114/6801; 75.2%). Of the people who died, 26.8% (1826/6801) had their last recorded AKPS >40. 
Similar numbers of assessments were carried out in the last week of life in those with and without 
cardio-respiratory disease and the last recorded clinical observation for each sub-population in the 
same order of magnitude. (Table 1) 
 
Breathlessness was higher in people with cardio-respiratory disease at all time points. Breathlessness, 
was also higher in people with better levels of function and increased in intensity most markedly in 
people with cardio-respiratory disease and higher levels of function. (Figure 1) People with a cardio-
respiratory life-limiting illness also had higher breathlessness intensity scores (adjusted mean 2.92 on 
a 0-10 NRS) than people with no documented cardio-respiratory diagnosis on each day (adjusted 
mean of 1.51; p=0.0001). This was seen in both AKPS groups (p <0.001 for each). This was seen in 
the AKPS strata dichotomised between 40 and 50 by diagnostic group (p <0.001 for each; Figure 1). 
These differences were clinically significant. [20] (Table 2) When split by cardio-respiratory status 
and AKPS 10, 20, 30 and ≥40, similar patterns are seen. (Web appendix 1) 
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In the adjusted mixed effects regression model accounting for repeated measures and adjusting for the 
available factors, independent predictors of worsening breathlessness were proximity to death (0.6; 
95% confidence interval (CI) 0.49,0.72), cardiorespiratory disease (breathlessness was 1.72 points 
worse; 95% CI 1.53, 1.90), while factors reducing the likelihood of breathlessness include poorer 
performance status (0.31; 95% CI 0.17, 0.45) and being female (0.28; 95% CI 0.18, 0.37). The 
relationship between breathlessness and a person’s level of function remained significant in the mixed 
effects regression model when interaction terms (week x diagnosis; week x function; week x 
diagnosis x function) were added with the only significant interaction term being diagnosis and 
function in the last week of life (p<0.0001), suggesting that in the last week, there is a real difference 
in trajectories between groups. 
 
Discussion 
This is the first study to stratify trajectories of breathlessness by functional status near death 
and whether the person has a cardio-respiratory life-limiting illness, extending previous 
analyses of breathlessness in the final weeks of life [7,13]. The increase in breathlessness in 
the last 21 days of life is seen least in the numerically largest of four sub-groups in the data: 
those with poorer levels of function and no documented cardio-respiratory disease. This 
group did not experience the same crescendo in breathlessness seen in the sub-group with 
better function and cardio-respiratory disease. Numerically, the smallest sub-group (better 
function, cardio-respiratory life-limiting illness) has the highest levels of breathlessness 
intensity across the last 21 days of life and experienced the largest absolute increase in 
breathlessness across that time.  
Previous studies have reported that breathlessness increases as death approaches (along with 
fatigue) whereas other symptoms tend to decrease. [7,10,13] Importantly in contrast to this 
new analysis, none of these studies adjusted for functional status. These three previous 
analyses adjusted for underlying life-limiting illnesses and defined higher levels of 
breathlessness in people with chronic respiratory disease. Bringing both factors into the 
current analysis sees the increase in breathlessness as death approaches disappear for the 
majority of patients, suggesting that the results of previous reports were being driven by 
increases seen in the breathlessness scores before their sudden death from this one sub-group: 
the people with higher levels of function and documented cardio-respiratory disease. Previous 
data may therefore have been skewed across the population in the weeks leading up to death 
by the data from this new identifiable sub-group.    
Chronic heart failure has a trajectory of acute exacerbations interspersed with periods of 
stability.[21] Recognition of worsening symptoms may allow intense support and recovery 
nearly to previous levels of function. In heart failure, as the disease severity worsens, death 
from progressive circulatory failure becomes relatively more common compared to sudden 
arrhythmic death. [22] This means that the predicted mode of death (sudden vs. non-sudden) 
may change with advancing symptoms and signs of disease and this helps better target 
interventions. For example cardiac defibrillators are not recommended for patients with New 
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York Heart Association (NYHA) class IV disease. [23] During these acute exacerbations or 
as a result of arrhythmias or infarction, a group of people with reasonable function died very 
rapidly.  
 
Apparent “sudden” cardiac death may have premonitory symptoms, most commonly chest 
pain or breathlessness, even in younger, apparently fit people, or may be secondary to another 
terminal event. [24,25] A cohort study of middle aged people suffering out of hospital sudden 
cardiac arrest found that some had had symptoms not just in the preceding 24 hours, but over 
the previous 4 weeks. [26] For this reason, information on events immediately surrounding 
the death and in the weeks leading up to death will help in the future to understand better the 
disease trajectory and identify any opportunities to modify clinical care. 
The worsening levels of breathlessness may represent events which could be treatable or, in 
the case of pulmonary emboli (PE), preventable. Pulmonary emboli are reported in 50% of 
autopsies in patients with cancer yet it is unclear whether these represent the sole cause of 
death, a contributory pathology within the agonal process [27,28] or a clinically incidental 
finding. Since 50% of hospice inpatients have evidence of asymptomatic deep vein 
thrombosis when sought, [29] and that hospice inpatients with a higher risk of venous 
thrombo-embolism (VTE) are more likely to have symptoms known to be related to VTE, 
[30] it is reasonable to consider VTE as a potential contributory factor to worsening 
breathlessness in those who die from inanition and those with a higher AKPS who experience 
a “sudden death”. Indeed it has been demonstrated that fatal, apparently sudden, PE are rarely 
asymptomatic and are dominated by tachycardia and breathlessness often with symptoms 
preceding death by days or weeks having been either ignored or misattributed.[31] People 
with incidentally diagnosed cancer-related VTE are often found on closer questioning to have 
had symptoms for some time[32,33]. 
Mechanisms 
The present findings confirm an increase in breathlessness intensity as death approaches, but 
the increase is more marked in people with cardio-respiratory disease and, then, those with 
better function. In this latter group, it is not apparent whether breathlessness intensity is a 
result of continued mobility, acute inter-current pathology, faster progression of the person’s 
primary condition or a mixture of all three. Acute pathology manifesting itself over several 
weeks is a likely contributor for many people given the magnitude of increase seen.  
 
People with lung cancer form a substantial proportion of the group with cardio-respiratory 
disease and higher levels of function. By contrast, in the sub-group of people with better 
levels of function and no documented cardio-respiratory disease (composed almost entirely of 
people with cancer), the pattern of markedly worsening breathlessness is not seen in the week 
before death, raising the possibility that VTE with a prodrome of breathlessness is less likely 
to be a contributing factor to sudden death. Such hypotheses can only be tested in a bespoke, 
prospective, longitudinal study.  
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Strengths and limitations 
This was a large, prospectively collected dataset used in clinical care, with low levels of 
missing data and an emphasis on patient-reported measures during clinical encounters. It has 
a large number of observations for each patient admitted to the service. The numbers of 
observations increase each week as death approaches. 
As this study does not include people admitted to hospital for their terminal care, the overall 
levels of breathlessness intensity may be under-estimated as people with conditions causing 
increasing breathlessness (acute coronary syndrome, arrhythmias, pulmonary embolism, 
acute lower respiratory tract infections) may be more likely to be admitted. Further, 
breathlessness as a reason for admission to hospital was not available either from this dataset.  
 
There are no data distinguishing between patient-reported measures and proxy measures. The 
latter are more likely to be needed in people with very poor levels of AKPS (10 or 20) and 
may under-estimate the intensity of breathlessness, although some studies have found family 
and specialist palliative care staff proxy assessments are reasonable valid for breathlessness. 
[34-37] Whether breathlessness was occurring at rest, on minimal exertion or, in the case of 
people with better functional status, on even greater levels of exertion cannot be derived from 
the available data.  
 
Data on cause of death were not available and a clinical review of several thousand cases was 
beyond the scope of this current project. Likewise, given the documented inaccuracy of death 
certificates, these were not data sought for this study. [38] 
 
A priori, the clinical categories were defined. Given the high correlation between prolonged 
exposure to tobacco, chronic obstructive pulmonary disease and lung cancer, it was decided 
to include primary (but not secondary) lung cancer in the group of patients with cardio-
respiratory diseases.  
 
Implications for clinical practice 
In people with metastatic cancer, the cut point of AKPS used in this study has prognostic 
significance. In one consecutive cohort, median survival in people with AKPS ≤40 was 29 
days compared with 146 days for those with AKPS >40 and poor physical well-being. [39] 
The sudden deaths described in this current analysis may therefore be a clinically important 
decrement in life expectancy especially if potentially reversible causes can be identified. This 
may be of great importance to many patients.  
There appears to be a warning of increasing breathlessness 7-9 days before death and, for 
some patients, this is likely to allow for potentially reversible causes to be investigated and 
treated, if that were the patient’s wish or to support the patient and family in their preferred 
place of death. This study suggests that worsening breathlessness should alert clinicians to an 
increased likelihood of death in people with reasonable function in the setting of documented 
cardio-respiratory disease. For people with better functional status, this raises the question of 
whether there are reversible causes for both the symptom and for what may be a premature 
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death in these circumstances. There appears to be a window for a clinical response to define 
potentially reversible factors.    
In addition, this study is a reminder that some causes of sudden death may be preventable. 
The incidence of VTE increases with cancer progression and it remains the second most 
common cause of death associated with malignancy. [27,28,40] Despite national policies  to 
implement VTE risk assessment and thromboprophylaxis of all people admitted to hospital, 
this has very low take up in palliative care units.[41] Here people with AKPS >40 may well 
be admitted for symptom management rather than end of life care, yet risk assessment for, 
and thromboprophylaxis of VTE is not standard practice. [41,42] Hospice and palliative care 
services should review their approach to risk assessment for VTE and thromboprophylaxis 
for those at higher risk. 
Implications for future research 
Future research should focus on whether any increase in breathlessness in people with a 
progressive, life-limiting disease has an underlying and potentially modifiable cause such as 
VTE, cardiac ischaemia, arrhythmia or infection.  For example, previous work has suggested 
systematic under-estimation of deep vein thromboses in this patient population. [43] 
The two trajectories that are identified in this study need to be documented with more clinical 
detail in a large, prospective, consecutive cohort study designed specifically to analyse these 
current findings. The first trajectory hypothesised is for people with an AKPS ≤40 who 
appear to have an inexorable decline associated with lower levels of breathlessness and are 
more likely to be experiencing progressive cachexia. The second trajectory hypothesised may 
represent the relatively unexpected death of patients with better functional status preceding 
death and much higher levels of breathlessness. Acute events including infections, cardiac 
ischaemia, arrhythmias, PE, or pericardial effusions, any of which may cause relatively acute 
worsening of breathlessness intensity in people with pre-existing cardio-respiratory disease, 
could help to explain the findings in this current study. If breathlessness in people with 
relatively good function and documented cardiorespiratory disease is a harbinger of 
impending death, this has significant clinical implications.  
There will also need to be a larger cohort that includes inpatients, and people who have 
presented to the emergency department to have a fuller picture of changes in breathlessness 
intensity by level of function at the end of life.   
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Table 1. Characteristics of a consecutive cohort of people referred to a community palliative care 
service between January 2011 and December 2014 including diagnostic group, and breathlessness 
and functional scores. (n=6801)  








n = 1,687 
Total 
 











1,017 (60.28) 3,751 (55.2) 
Female 2,380 
(46.54) 
670 (39.72) 3,050 (44.8) 
Age at death (years) Mean (SD) 71.0 (16.0) *72.7 (11.7) 71.5 (15.1) 




Primary lung cancer 1,398 (20.6) 
Respiratory failure 153 (2.3) 
Cardiac failure 136 (2.00) 
No documented cardio-respiratory disease 5,114 (75.2) 
Time from referral to 
death (days) 
Median (IQR) 40 (78) **51 (84) 42 (79) 
Observations per 
patient in the last 
week of life 

















Days Median  
>4
0 (8  7 1 ≤4
0 0 0 
Breathlessness 
(0-10 NRS) Median (IQR) 0 (4) **3 (4) 1 (4) 
AKPS (n%) >40      544 (32.2) 1,282 (25.1) 1,826 (26.8) ≤40 3,831 (74.9) 1,143 (67.7) 4,974 (73.2) 
*p=0.0001 – the sub-group with documented cardio-respiratory disease were older than those without. 
**p=0.0001 – the sub-group with documented cardio-respiratory disease have a longer length of time between referral 
and death 
**p=0.0001 the sub-group with documented cardio-respiratory disease experience greater breathlessness 
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Table 2: Multivariable model of breathlessness in relation to time before death, diagnosis and 
function adjusted for confounders.  
Breathlessness Coefficient p >|z| 95% Confidence Interval 
Week 3   
Week 2 0.203027 <0.001 0.11492 0.291135 
Week 1 0.607341 <0.001 0.490567 0.724115 
          
Age 0.001382 0.401 -0.00184 0.004608 
Length of Stay 0.000298 0.240 -0.0002 0.000796 
          
Non-Cardiorespiratory Diagnosis   
 Cardiorespiratory 1.716373 <0.001 1.528672 1.904075 
          
Karnofsky  >40   
                    <=40 -0.31377 <0.001 -0.45288 -0.17466 
          
Male   
Female -0.27498 <0.001 -0.37145 -0.17852 
          
Interaction between week, 
functional status and 
cardiorespiratory diagnoses   
Week 3#<=40#Cardiorespiratory -0.14737 0.470 -0.54713 0.252387 
Week 2#<=40#Cardiorespiratory -0.01479 0.926 -0.32852 0.298939 
Week 1#<=40#Cardiorespiratory -0.71082 <0.001 -0.956 -0.46564 
Mixed effects linear regression model, accounting for repeated measurements and clustering over 
individuals; 48,385 observations in 6,768 patients with complete data on the model variables. Three 
interaction terms are included. 
 
